Nile Therapeutics, Inc. (Nasdaq: NLTX), announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company’s lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

More: continued here

Filed under: Cardiovascular on July 16th, 2008

Nile Therapeutics, Inc. (Nasdaq: NLTX), announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company’s lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

More: continued here

Filed under: Clinical Trials on July 16th, 2008